KalVista Pharmaceuticals (NASDAQ:KALV) Price Target Raised to $27.00

KalVista Pharmaceuticals (NASDAQ:KALV) had its price target increased by HC Wainwright from $20.00 to $27.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for KalVista Pharmaceuticals’ Q4 2025 earnings at ($0.35) EPS, FY2026 earnings at ($1.71) EPS, FY2027 earnings at ($0.15) EPS, FY2028 earnings at $1.62 EPS, FY2029 earnings at $3.37 EPS and FY2030 earnings at $4.08 EPS.

A number of other research analysts have also recently issued reports on the company. Leerink Partners lifted their price target on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an “outperform” rating in a report on Monday. Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Finally, Jones Trading restated a “buy” rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, KalVista Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $26.29.

KalVista Pharmaceuticals Stock Down 3.0%

NASDAQ:KALV opened at $15.51 on Tuesday. The firm has a market cap of $771.16 million, a PE ratio of -4.17 and a beta of -0.04. KalVista Pharmaceuticals has a 12 month low of $7.30 and a 12 month high of $16.32. The company’s 50-day moving average price is $12.55 and its two-hundred day moving average price is $11.19.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($2.86). During the same period last year, the company posted ($1.07) earnings per share. On average, research analysts expect that KalVista Pharmaceuticals will post -3.56 EPS for the current fiscal year.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 32,979 shares of KalVista Pharmaceuticals stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total transaction of $517,440.51. Following the completion of the sale, the chief executive officer owned 369,595 shares of the company’s stock, valued at approximately $5,798,945.55. The trade was a 8.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul K. Audhya sold 2,776 shares of the stock in a transaction on Monday, May 19th. The shares were sold at an average price of $11.84, for a total value of $32,867.84. Following the completion of the transaction, the insider directly owned 106,611 shares in the company, valued at approximately $1,262,274.24. This trade represents a 2.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold 48,878 shares of company stock worth $723,617 over the last 90 days. 10.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. Boxer Capital Management LLC bought a new stake in shares of KalVista Pharmaceuticals in the 4th quarter valued at about $13,467,000. Octagon Capital Advisors LP acquired a new position in KalVista Pharmaceuticals during the fourth quarter valued at approximately $11,604,000. Frazier Life Sciences Management L.P. increased its stake in KalVista Pharmaceuticals by 32.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company’s stock valued at $41,400,000 after purchasing an additional 1,200,000 shares in the last quarter. Stempoint Capital LP bought a new stake in KalVista Pharmaceuticals in the fourth quarter valued at approximately $8,409,000. Finally, Vestal Point Capital LP raised its holdings in KalVista Pharmaceuticals by 19.3% in the fourth quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company’s stock worth $40,402,000 after purchasing an additional 770,000 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).